WHITBY PHARMACEUTICAL ACQUIRES 11 GLAXO PRODUCTS with aggregate annual sales of $9.5 mil. Whitby announced the purchase Jan. 19. The purchase price was not disclosed. Whitby Pharmaceuticals is the new name (adopted in Sept. 1989) by chemical manufacturer Ethyl Corp's drug marketing business. Ethyl established the drug marketing effort in 1987 as Ethyl Pharmaceutical Inc. Ethyl's finished drug business is made up of Birmingham, Alabama-based Russ Pharmaceuticals (acquired by Ethyl in March, 1989) and the former Nelson Research and Development (acquired in 1987). Nelson has been rechristened Whitby Research. Whitby subsidiary Russ will market the products, which are produced by a contract manufacturer. Russ currently markets a single product line, the Lortab series of hydrocondone-based prescription analgesics. The products involved in the deal are Trinsicon hematinic concentrate, Trinsicon M hematinic modified (without folic acid), vitamin formulations Vicon-C, Vicon Forte, Vicon Plus, and Vi-Zac, the hemorrhoid cream Corticaine (hydrocortisone acetate), asthma treatment Amesec, Ethatab, used in vascular disorders, laxative Athrocholin and antihistamines Histabid and Histabid Duracaps.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
